Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
NBC Chicago26d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now ...
ABC News27d
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
Eli Lilly estimates that is about 15-20 million adults in the U.S. An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, March 28, 2024. Obstructive sleep apnea ...
Yahoo Finance29d
Egyptian Drug Authority approves Lilly and EVA’s insulin injection
Eli Lilly and EVA Pharma have announced approval from the Egyptian Drug Authority for the human insulin glargine injection to treat type 1 and type 2 diabetic patients. EVA Pharma manufactures the ...
Yahoo Finance27d
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s supply is currently meeting or exceeding demand and will continue to ...
Seeking Alpha4d
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...
FiercePharma26d
Lilly's Zepbound scores 2nd approval with landmark FDA nod in obstructive sleep apnea
Christmas has come early for Eli Lilly this year ... its latest approval decision on Lilly’s phase 3 SURMOUNT-OSA trials. The trials assessed the injection at 10-mg and 15-mg doses in patients ...
Pharmabiz28d
Lilly and EVA Pharma receive Egyptian Drug Authority approval for insulin glargine injection and release of locally manufactured insulin in Egypt
The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company. Launched in 2022, the collaboration aims to deliver a ...